Group 1 - The core viewpoint of the article highlights that Sino Biopharmaceutical-B (02591) has seen a significant stock price increase of over 50% in four trading days, with a current price of 44.68 HKD and a trading volume of 35.37 million HKD [1] - On November 21, the results of the Hang Seng Index series quarterly review were released, and Sino Biopharmaceutical was included in the Hang Seng Composite Index, with the change effective from December 8, 2025 [1] - According to CICC's forecast, Sino Biopharmaceutical is expected to meet the criteria for inclusion in the Hong Kong Stock Connect [1] Group 2 - Sino Biopharmaceutical is focused on the field of metabolic diseases and has a pipeline of innovative drugs targeting conditions such as diabetes, obesity, and non-alcoholic fatty liver disease, all of which are self-developed and possess global intellectual property rights [1] - The company has a comprehensive global research and market layout [1]
港股异动 | 银诺医药-B(02591)再涨近7% 四个交易日股价累涨超50% 将被纳入恒生综合指数